Triderm

Relieves inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. ANDA 88042, held by Crown Labs. Triamcinolone Acetonide.

As of Nov 15, 2026, ANDA 88042 (Triderm), held by Crown Labs, was first approved by FDA on Mar 19, 1984, with 4 approved supplements and 0 published complete response letters.

First approved: Mar 19, 1984
Supplements approved: 4
Complete response letters: 0

What It's For

From the FDA-approved label (Indications and Usage)

INDICATIONS & USAGE Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

Full prescribing information on DailyMed ↗

Approvals and New Uses

The original application and every efficacy supplement, newest first; all 5 submissions below

Date	Submission	Status	Documents
Mar 19, 1984	Original application	Approved	None posted

Products

3 strengths and forms


Triderm0.1% · cream;topical	Triamcinolone Acetonide	Rx
Triderm0.025% · cream;topical	Triamcinolone Acetonide	Rx
Triderm0.5% · cream;topical	Triamcinolone Acetonide	Rx

All 5 submissions, including labeling and manufacturing supplements


Jan 7, 2015	Supplement 5Labeling	Approved	None posted
Aug 14, 1996	Supplement 3Labeling	Approved	None posted
Jul 10, 1991	Supplement 2Labeling	Approved	None posted
Jun 5, 1990	Supplement 1Labeling	Approved	None posted
Mar 19, 1984	Original application	Approved	None posted

Identifiers

Application: ANDA 88042
Drugs@FDA: Overview at FDA
Company: Crown Laboratories

Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters